Aripiprazole

Efficacy and tolerability profile of a novel-acting atypical antipsychotic

Peter F Buckley

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (D2) receptors and at serotonin (5HT1A) receptors. Placebo-controlled comparative trials of aripiprazole confirm efficacy for positive, negative and general psychopathology. Treatment-emergent adverse effects appear low. Aripiprazole is associated with low propensity for extrapyramidal side effects, an absence hyperprolactinemia and a low propensity for weight gain. Aripiprazole's clinical role will be determined by clinical experience, additional phase IV studies, and comparative information for this agent with respect to the efficacy and tolerability profiles of other atypical antipsychotic medications.

Original languageEnglish (US)
Pages (from-to)145-151
Number of pages7
JournalDrugs of Today
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Antipsychotic Agents
Hyperprolactinemia
Dopamine D2 Receptors
Serotonin Receptors
Psychopathology
Weight Gain
Placebos
Aripiprazole
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aripiprazole : Efficacy and tolerability profile of a novel-acting atypical antipsychotic. / Buckley, Peter F.

In: Drugs of Today, Vol. 39, No. 2, 01.02.2003, p. 145-151.

Research output: Contribution to journalReview article

@article{abcf9f434f724ad78738efa4bc8be67f,
title = "Aripiprazole: Efficacy and tolerability profile of a novel-acting atypical antipsychotic",
abstract = "Aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (D2) receptors and at serotonin (5HT1A) receptors. Placebo-controlled comparative trials of aripiprazole confirm efficacy for positive, negative and general psychopathology. Treatment-emergent adverse effects appear low. Aripiprazole is associated with low propensity for extrapyramidal side effects, an absence hyperprolactinemia and a low propensity for weight gain. Aripiprazole's clinical role will be determined by clinical experience, additional phase IV studies, and comparative information for this agent with respect to the efficacy and tolerability profiles of other atypical antipsychotic medications.",
author = "Buckley, {Peter F}",
year = "2003",
month = "2",
day = "1",
doi = "10.1358/dot.2003.39.2.799421",
language = "English (US)",
volume = "39",
pages = "145--151",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Aripiprazole

T2 - Efficacy and tolerability profile of a novel-acting atypical antipsychotic

AU - Buckley, Peter F

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (D2) receptors and at serotonin (5HT1A) receptors. Placebo-controlled comparative trials of aripiprazole confirm efficacy for positive, negative and general psychopathology. Treatment-emergent adverse effects appear low. Aripiprazole is associated with low propensity for extrapyramidal side effects, an absence hyperprolactinemia and a low propensity for weight gain. Aripiprazole's clinical role will be determined by clinical experience, additional phase IV studies, and comparative information for this agent with respect to the efficacy and tolerability profiles of other atypical antipsychotic medications.

AB - Aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (D2) receptors and at serotonin (5HT1A) receptors. Placebo-controlled comparative trials of aripiprazole confirm efficacy for positive, negative and general psychopathology. Treatment-emergent adverse effects appear low. Aripiprazole is associated with low propensity for extrapyramidal side effects, an absence hyperprolactinemia and a low propensity for weight gain. Aripiprazole's clinical role will be determined by clinical experience, additional phase IV studies, and comparative information for this agent with respect to the efficacy and tolerability profiles of other atypical antipsychotic medications.

UR - http://www.scopus.com/inward/record.url?scp=0037321460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037321460&partnerID=8YFLogxK

U2 - 10.1358/dot.2003.39.2.799421

DO - 10.1358/dot.2003.39.2.799421

M3 - Review article

VL - 39

SP - 145

EP - 151

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -